Skip to main content
Erschienen in: Journal of Endocrinological Investigation 11/2018

01.11.2018 | Original Article

Specificity of late-night salivary cortisol measured by automated electrochemiluminescence immunoassay for Cushing’s disease in an obese population

verfasst von: J. Aberle, C. Schulze zur Wiesch, J. Flitsch, J. Veigel, G. Schön, R. Jung, F. Reining, A. Lautenbach, R. Rotermund, N. Riedel

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 11/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Data about the specificity of late-night salivary cortisol (LNSC) in obese subjects are still conflicting. Therefore, with this study, we aimed to evaluate the specificity of LNSC measurement in an obese cohort with or without type 2 diabetes mellitus (T2DM) using an automated electrochemiluminescence immunoassay (ECLIA).

Methods

A total number of 157 patients involving 40 healthy subjects (HS) with BMI < 25 kg/m2, 83 obese subjects (OS) with BMI ≥ 35 kg/m2, and 34 histopathologically proven Cushing’s disease (CD) were included. All patients underwent LNSC testing. Salivary cortisol was measured at 11 p.m. for all groups using an ECLIA. Reference range was established using values of LNSCs of HS and ROC curves were used to determine diagnostic cutoffs.

Results

In the HS group, mean LNSC was 4.7 nmol/l (SD ± 3.1), while the OS group had a mean value of 10.9 nmol/l (SD ± 7.5) and the CD group of 19.9 nmol/l (SD ± 15.4). All groups differed significantly (p < 0.001). The ROC analysis of CD against HS alone showed a sensitivity of 85.3% and a specificity of 87.5% with a cut-off value of 8.3 nmol/l. The ROC analysis between OS and CD showed a maximum sensitivity of 67.6% and specificity of 78.3% for a cut-off value of 12.3 nmol/l. Taken both (HS and OS) groups together against the CD group, ROC analysis showed a maximum sensitivity of 67.6% and specificity of 85.4% for a cut-off value of 12.3 nmol/l. No correlation was found between BMI, T2DM, and LNSC for all groups.

Conclusions

In our obese cohort, we found that LNSC assayed by ECLIA had a low specificity in the diagnosis of CD.
Literatur
1.
Zurück zum Zitat Nieman LK, Biller BMK, Findling JW et al (2008) The diagnosis of Cushing’s disease: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93(5):1526–1540CrossRef Nieman LK, Biller BMK, Findling JW et al (2008) The diagnosis of Cushing’s disease: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93(5):1526–1540CrossRef
2.
Zurück zum Zitat Mechanick JI, Youdim A, Jones DB et al (2013) Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery. Surg Obes Relat Dis 9:159–191CrossRef Mechanick JI, Youdim A, Jones DB et al (2013) Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery. Surg Obes Relat Dis 9:159–191CrossRef
3.
Zurück zum Zitat Beko G, Varga I, Glaz E et al (2010) Cutoff values of midnight salivary cortisol for the diagnosis of overt hypercortisolism are highly influenced by methods. Clin Chim Acta 411(5–6):364–367CrossRef Beko G, Varga I, Glaz E et al (2010) Cutoff values of midnight salivary cortisol for the diagnosis of overt hypercortisolism are highly influenced by methods. Clin Chim Acta 411(5–6):364–367CrossRef
4.
Zurück zum Zitat Bukan A, Dere H, Jadhav S et al (2015) The performance and reproducibility of late-night salivary cortisol estimation by enzyme immunoassay for screening cushing disease. Endocr Pract 21(2):158–164CrossRef Bukan A, Dere H, Jadhav S et al (2015) The performance and reproducibility of late-night salivary cortisol estimation by enzyme immunoassay for screening cushing disease. Endocr Pract 21(2):158–164CrossRef
5.
Zurück zum Zitat Ellis E, Chin PKL, Hunt PJ et al (2012) Is late-night salivary cortisol a better screening test for possible cortisol excess than standard screening tests in obese patients with Type 2 diabetes? N Z Med J 125(1353):47–58PubMed Ellis E, Chin PKL, Hunt PJ et al (2012) Is late-night salivary cortisol a better screening test for possible cortisol excess than standard screening tests in obese patients with Type 2 diabetes? N Z Med J 125(1353):47–58PubMed
6.
Zurück zum Zitat Belaya ZE, Iljin AV, Melnichenko GA et al (2012) Diagnostic performance of late-night salivary cortisol measured by automated electrochemiluminescence immunoassay in obese and overweight patients referred to exclude Cushing’s syndrome. Endocrine 41(3):494–500CrossRef Belaya ZE, Iljin AV, Melnichenko GA et al (2012) Diagnostic performance of late-night salivary cortisol measured by automated electrochemiluminescence immunoassay in obese and overweight patients referred to exclude Cushing’s syndrome. Endocrine 41(3):494–500CrossRef
7.
Zurück zum Zitat Yaneva M, Kirilov G, Zacharieva S (2009) Midnight salivary cortisol, measured by highly sensitive electrochemiluminescence immunoassay, for the diagnosis of Cushing’s syndrome. Cent Eur J Med 4(1):59–64 Yaneva M, Kirilov G, Zacharieva S (2009) Midnight salivary cortisol, measured by highly sensitive electrochemiluminescence immunoassay, for the diagnosis of Cushing’s syndrome. Cent Eur J Med 4(1):59–64
8.
Zurück zum Zitat Deutschbein T, Petersenn S (2013) Screening for Cushing’s syndrome: new immunoassays require adequate normative data. Horm Metab Res 45(2):118–123CrossRef Deutschbein T, Petersenn S (2013) Screening for Cushing’s syndrome: new immunoassays require adequate normative data. Horm Metab Res 45(2):118–123CrossRef
9.
Zurück zum Zitat Putignano P, Toja P, Dubini A et al (2003) Midnight salivary cortisol versus urinary free and midnight serum cortisol as screening tests for cushing’s syndrome. J Clin Endocrinol Metab 88(9):4153–4157CrossRef Putignano P, Toja P, Dubini A et al (2003) Midnight salivary cortisol versus urinary free and midnight serum cortisol as screening tests for cushing’s syndrome. J Clin Endocrinol Metab 88(9):4153–4157CrossRef
10.
Zurück zum Zitat Baid SK, Rubino D, Sinaii N, Ramsey S, Frank A, Nieman LK (2009) Specificity of screening tests for cushing’s syndrome in an overweight and obese population. J Clin Endocrinol Metab 94(10):3857–3864CrossRef Baid SK, Rubino D, Sinaii N, Ramsey S, Frank A, Nieman LK (2009) Specificity of screening tests for cushing’s syndrome in an overweight and obese population. J Clin Endocrinol Metab 94(10):3857–3864CrossRef
11.
Zurück zum Zitat Raff H, Magill SB (2016) Is the hypothalamic-pituitary-adrenal axis disrupted in type 2 diabetes mellitus? Endocrine 54(2):273–275CrossRef Raff H, Magill SB (2016) Is the hypothalamic-pituitary-adrenal axis disrupted in type 2 diabetes mellitus? Endocrine 54(2):273–275CrossRef
12.
Zurück zum Zitat Donath MY, Shoelson SE (2011) Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 11(2):98–107CrossRef Donath MY, Shoelson SE (2011) Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 11(2):98–107CrossRef
13.
Zurück zum Zitat Cucak H, Grunnet LG, Rosendahl A (2014) Accumulation of M1-like macrophages in type 2 diabetic islets is followed by a systemic shift in macrophage polarization. J Leukoc Biol 95(1):149–160CrossRef Cucak H, Grunnet LG, Rosendahl A (2014) Accumulation of M1-like macrophages in type 2 diabetic islets is followed by a systemic shift in macrophage polarization. J Leukoc Biol 95(1):149–160CrossRef
14.
Zurück zum Zitat Steffensen C, Thomsen H, Dekkers OM et al (2016) Low positive predictive value of midnight salivary cortisol measurement to detect hypercortisolism in type 2 diabetes. Clin Endocrinol (Oxf) 85:202–206CrossRef Steffensen C, Thomsen H, Dekkers OM et al (2016) Low positive predictive value of midnight salivary cortisol measurement to detect hypercortisolism in type 2 diabetes. Clin Endocrinol (Oxf) 85:202–206CrossRef
15.
Zurück zum Zitat Liu H, Bravata DM, Cabaccan J et al (2005) Elevated late-night salivary cortisol levels in elderly male type 2 diabetic veterans. Clin Endocrinol (Oxf) 63(6):642–649CrossRef Liu H, Bravata DM, Cabaccan J et al (2005) Elevated late-night salivary cortisol levels in elderly male type 2 diabetic veterans. Clin Endocrinol (Oxf) 63(6):642–649CrossRef
16.
Zurück zum Zitat Valentine AR, Raff H, Liu H et al (2011) Salivary cortisol increases after bariatric surgery in women. Horm Metab Res 43(8):587–590CrossRef Valentine AR, Raff H, Liu H et al (2011) Salivary cortisol increases after bariatric surgery in women. Horm Metab Res 43(8):587–590CrossRef
17.
Zurück zum Zitat Putignano P, Dubini A, Toja P et al (2001) Salivary cortisol measurement in normal-weight, obese and anorexic women: comparison with plasma cortisol. Eur J Endocrinol 145(2):165–171CrossRef Putignano P, Dubini A, Toja P et al (2001) Salivary cortisol measurement in normal-weight, obese and anorexic women: comparison with plasma cortisol. Eur J Endocrinol 145(2):165–171CrossRef
18.
Zurück zum Zitat Trilck M, Flitsch J, Lüdecke DK et al (2005) Salivary cortisol measurement—a reliable method for the diagnosis of Cushing’s syndrome. Exp Clin Endocrinol Diabetes 113(4):225–230CrossRef Trilck M, Flitsch J, Lüdecke DK et al (2005) Salivary cortisol measurement—a reliable method for the diagnosis of Cushing’s syndrome. Exp Clin Endocrinol Diabetes 113(4):225–230CrossRef
20.
Zurück zum Zitat Oltmanns KM, Dodt B, Schultes B et al (2006) Cortisol correlates with metabolic disturbances in a population study of type 2 diabetic patients. Eur J Endocrinol 154(2):325–331CrossRef Oltmanns KM, Dodt B, Schultes B et al (2006) Cortisol correlates with metabolic disturbances in a population study of type 2 diabetic patients. Eur J Endocrinol 154(2):325–331CrossRef
21.
22.
Zurück zum Zitat Javorsky BR, Carroll TB, Tritos NA et al (2015) Discovery of Cushing’s syndrome after bariatric surgery: multicenter series of 16 patients. Obes Surg 25(12):2306–2313CrossRef Javorsky BR, Carroll TB, Tritos NA et al (2015) Discovery of Cushing’s syndrome after bariatric surgery: multicenter series of 16 patients. Obes Surg 25(12):2306–2313CrossRef
Metadaten
Titel
Specificity of late-night salivary cortisol measured by automated electrochemiluminescence immunoassay for Cushing’s disease in an obese population
verfasst von
J. Aberle
C. Schulze zur Wiesch
J. Flitsch
J. Veigel
G. Schön
R. Jung
F. Reining
A. Lautenbach
R. Rotermund
N. Riedel
Publikationsdatum
01.11.2018
Verlag
Springer International Publishing
Erschienen in
Journal of Endocrinological Investigation / Ausgabe 11/2018
Elektronische ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-018-0870-8

Weitere Artikel der Ausgabe 11/2018

Journal of Endocrinological Investigation 11/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

NSCLC: Progressionsfreies Überleben unter Osimertinib fast versiebenfacht

06.06.2024 ASCO 2024 Kongressbericht

Erste Ergebnisse der Phase-III-Studie LAURA etablieren Osimertinib als neuen Therapiestandard für Menschen mit nicht-resezierbarem, EGFR-mutiertem, nicht-kleinzelligem Lungenkarzinom im Stadium III, die nach definitiver Radiochemotherapie progressionsfrei sind. Auf der ASCO-Tagung wurden diese beeindruckenden Ergebnisse besprochen.

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gute molekulare Response, aber seltener ernste Nebenwirkungen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.